

Polysaccharide Based Implantable Drug Delivery

Subjects: [Transplantation](#)

Contributor: Sagar Salave , Dhvani Rana , Amit Sharma , K. Bharathi , Raghav Gupta , Shubhangi Khode , Derajram Benival , Nagavendra Kommineni

Implantable drug delivery systems advocate a wide array of potential benefits, including effective administration of drugs at lower concentrations and fewer side-effects whilst increasing patient compliance. Amongst several polymers used for fabricating implants, biopolymers such as polysaccharides are known for modulating drug delivery attributes as desired.

[implants](#)[polysaccharides](#)[biopolymers](#)[drug delivery](#)

1. Introduction

Implantable drug delivery systems offer wide therapeutic applications by providing targeted local delivery of drugs and long-term therapeutic effects. This effective delivery with lower drug concentrations results in minimizing the potential side-effects and ultimately enhancing the efficacy of treatment ^{[1][2]}. Drugs that would ordinarily be inappropriate for oral administration can be delivered as implants since, following implantation, the drugs would circumvent hepatic first pass metabolism and would also escape chemical degradation in the intestine and stomach, resulting in improved bioavailability. Controlled drug release over an extended period of time can be achieved by employing this system. The fluctuations in plasma drug concentrations such as attainment of peaks and valleys that occur from repeated intermediate dosing are avoided ^{[2][3]}.

From the standpoint of patient compliance, the implantation might be relatively invasive, but good compliance can be achieved owing to a single-time implantation. Further, occurrence of any adverse effect that necessitates termination of treatment can be achieved by early removal of the implants. Moreover, hospitalization or persistent monitoring by healthcare staff might not be necessary for chronic conditions ^{[2][3]}. **Figure 1** illustrates the advantages of an implantable drug delivery system.




Figure 1. Design features of implantable drug delivery system.

2. Classification of Implantable Drug Delivery Devices

Implantable devices for drug delivery can be broadly categorized into two major groups: active implants and passive implants. Passive implants depend upon a diffusion-controlled phenomena to achieve drug release, whereas active systems are dependent on energy that serves as the key driving factor to control drug release. Further, passive systems are biodegradable or non-biodegradable and are simple with no moving parts. They use different kinds of polymers that enable to achieve membrane-controlled drug release kinetics from the delivery systems. Active or dynamic drug delivery implants are relatively complex but offer greater control over the drug release [1][2].

Biopolymers arise from living organisms whose degradation products are not immunogenic. Biopolymers offer several benefits over synthetic polymers, including a well-organized structure, degradability, and renewability, all of which possess the ability to be utilised in the design of therapeutic devices like implants. A wide range of alternative uses of biopolymers are also evident, including their use as scaffolds for tissue engineering owing to its three-dimensional porous structures, as controlled or sustained release vehicles for drug delivery, and as temporary prostheses [4][5] (Figure 2).




Figure 2. Drug delivery and biomedical applications of polysaccharides.

Polysaccharides belong to a diverse group of biopolymers comprising repetitive mono- or disaccharide units that are connected through enzyme-hydrolysable glycosidic linkages. These are widely used as controlled release drug carriers that impart remarkable physiological and physicochemical properties such as biocompatibility, biodegradability, and low immunogenicity [6]. Polysaccharide-based biopolymers are classified based on the source of their origin (Table 1).

Table 1. Classification of polysaccharide-biopolymers [5].

Origin	Polysaccharides
Plant/algal	Starch (amylose/amylopectin), cellulose, agar, alginate, carrageenan, pectin, konjac, guar gum
Animal	Chitin/chitosan, hyaluronic acid
Bacterial	Xanthan, dextran, gellan, levan, curdlan, polygalactosamine
Fungal	Pullulan, elsinan, yeast glucans

Moreover, advanced drug delivery systems based on polysaccharides can also improve the drug's **References** due to their capacity to entrap the drug molecules in its interspaces, biocompatibility, and ability to provide a controlled release of the drug molecules [6]. All these characteristics make them ideal for use in

implantable drug delivery. **Figure 3** dictates the prime attributes of polysaccharides, making them ideal for the development of implants.

1. Dash, A.; Cudworth, G. Therapeutic applications of implantable drug delivery systems. *J. Pharmacol. Toxicol. Methods* 1998, 40, 1–12.
2. Stewart, S.A.; Dominguez-Robles, J.; Donnelly, R.F.; Larraneta, E. Implantable Polymeric Drug Delivery Devices: Classification, Manufacture, Materials, and Clinical Applications. *Polymers* 2018, 10, 1379.
3. Kumar, A.; Pillai, J. Implantable Drug Delivery Systems: An Overview. In *Nanostructures for the Engineering of Cells, Tissues and Organs: From Design to Applications*; Grumezescu, A.M., Ed.; Elsevier: Amsterdam, The Netherlands, 2018; pp. 473–511.
4. Yadav, P.; Yadav, H.; Shah, V.G.; Shah, G.; Dhaka, G. Biomedical Biopolymers, Their Origin and Evolution in Biomedical Sciences: A Systematic Review. *J. Clin. Diagn. Res.* 2015, 9, ZE21-5.
5. Rebelo, R.; Fernandes, M.; Figueiro, R. Biopolymers in Medical Implants: A Brief Review. *Procedia Eng.* 2017, 200, 236–243.
6. Prasher, P.; Sharma, M.; Mehta, M.; Satija, S.; Aljabali, A.A.; Tambuwala, M.M.; Anand, K.; Sharma, N.; Dureja, H.; Jha, N.K.; et al. Current-status and applications of polysaccharides in drug delivery systems. *Colloids Interface Sci. Commun.* 2021, 42, 100418.

Figure 3. Unique characteristic of polysaccharides suitable for drug delivery and biomedical applications.

3. Strategies to Employ Polysaccharides in Implant Formulation

7. Yang, Y.; Wu, H.; Fu, Q.; Xie, X.; Song, Y.; Xu, M.; Li, J. 3D-printed polycaprolactone-chitosan based drug delivery implants for personalized administration. *Mater. Des.* 2022, 214, 110394.
8. López-Valverde, N.; López-Valverde, A.; Cortés, M.P.; Rodríguez, C.; De Sousa, B.M.; Aragonese, J.M. Bone Quantification Around Chitosan-Coated Titanium Dental Implants: A Preliminary Study by Micro-CT Analysis in Jaw of a Canine Model. *Front. Bioeng. Biotechnol.* 2022, 10, 858786.

9. Nganga, S.; Travan, A.; Marsich, E.; Donati, I.; Süderling, E.; Moritz, N.; Paoletti, S.; Vallittu, P.K. In vitro antimicrobial properties of silver–polysaccharide coatings on porous fiber-reinforced composites for bone implants. *J. Mater. Sci. Mater. Electron.* 2013, 24, 2775–2785.
10. AlNufaiy, B.M.; Lambarte, R.N.A.; Al-Haradani, B. The Osteogenetic Potential of Chitosan Coated Implant: An In Vitro Study. *Biomed. Res. Int. J. Biomed. Res.* 2020, 16, 44–49.
11. McDonald, M.; D'Aversa, G.; Perry, H.D.; Wittmann, J.R.; Donnenfeld, E.D.; Nelinson, D.S. Hydroxypropyl cellulose ophthalmic inserts (lacrisert) reduce the signs and symptoms of dry eye syndrome and improve patient quality of life. *Trans. Am. Ophthalmol. Soc.* 2009, 107, 214–221.
12. Masina, N.; Choonara, Y.E.; Kumar, P.; du Toit, L.C.; Govender, M.; Indermun, S.; Pillay, V. A review of the chemical modification techniques of starch. *Carbohydr. Polym.* 2017, 157, 1226–1236.

13. Liu, H.; Ramsden, L.; Corke, H. Physical properties and enzymatic digestibility of hydroxypropylated ae, wx, and normal maize starch. *Carbohydr. Polym.* 1999, 40, 175–182.

Figure 4. Schematic representation of strategies employed to develop polysaccharide-based implants.

14. Adetunji, A.O. *Chemically Modified Starches as Excipients in Pharmaceutical Dosage Forms*. In: *Chemical Properties of Starch*, Emeje, M., Ed., IntechOpen: London, UK, 2020.

For chemical properties of starch, Emeje, M., Ed., IntechOpen: London, UK, 2020. inferior eyelid and is indicated for the treatment of dry eye disease. The insert is entirely made up of hydroxypropyl cellulose (HPC), a cellulose-based polysaccharide, and dissolves gradually in the tear fluid [11]. The drug release from implants can also be modified by combining the matrix polymer with a secondary material, like a pore former, depending on the material properties of the implant. Certain polysaccharides are employed for their specific functions, e.g., water

15. Lemos, P.V.F.; Marcelino, H.R.; Cardoso, L.G.; de Souza, C.O.; Druzian, J.I. Starch chemical modifications applied to drug delivery systems: From fundamentals to FDA-approved raw

materials. *Int. J. Biol. Macromol.* 2021, 184, 218–234.

4. Polysaccharide Based Polymers

17. Hsieh, Y.-C.; Yano, H.; Nogi, M.; Eichhorn, S.J. An estimation of the Young's modulus of bacterial cellulose filaments. *Cellulose* 2008, 15, 507–513.

18. Nakagaito, A.N.; Iwamoto, S.; Yano, H. Bacterial cellulose: The ultimate nanoscale cellulose morphology for the production of high-strength composites. *Appl. Phys. A: Mater. Sci. Process.* 2005, 80, 93–97.

Chemical modifications include esterification, etherification, oxidation, cross-linking, and cationization, that ultimately lead to alteration in the physicochemical properties of starch. Each glucose unit in starch consists of three free hydroxyl groups that, in the presence of oxidizing agents, under controlled temperature and pH

19. Brown, R.M.; Willison, J.H.; Richardson, C.L. Cellulose biosynthesis in *Acetobacter xylinum*. Visualization of the site of synthesis and direct measurement of the in vivo process. *Proc. Natl. Acad. Sci. USA* 1976, 73, 4565–4569.

20. Trovati, E.; Oliveira, L.; Freire, C.S.; Silvestre, A.; Neto, C.; Pinto, J.J.C.; Gandini, A. Novel bacterial cellulose-acrylic resin nanocomposites. *Compos. Sci. Technol.* 2010, 70, 1148–1153.

21. Saito, T.; Kimura, S.; Nishiyama, Y.; Isega, A. Cellulose Nanofibers Prepared by TEMPO-Mediated Oxidation of Native Cellulose. *Biomacromolecules* 2007, 8, 2485–2491.

22. Zimnitsky, D.S.; Yurkshtovich, T.L.; Bychkovsky, P.M. Synthesis and Characterisation of Oxidized hydroxypropyl groups, being hydrophilic in nature, prevent the separation of water through syneresis, thus enhancing the freeze-thaw stability [13]. Acetylated starch is an example of ester modification, where the

23. Müller, F.A.; Müller, G.; Hoffer, A.; Griebel, R.; Wenzel, M.; Staudenmann, R. Cellulose-based scaffold: Hydrogel for cartilage tissue engineering. *Biomaterials* 2006, 27, 3955–3963.

24. Jeschke, M.G.; Sandmann, G.; Schubert, T.; Klein, D. Effect of oxidized regenerated cellulose/collagen matrix on dermal and epidermal healing and growth factors in an acute wound. *Wound Repair Regen.* 2005, 13, 324–331.

25. Bassetto, F.; Vindigni, V.; Scarpa, C.; Botti, G.; Botti, G. Use of Oxidized-Regenerated Cellulose to Stop Bleeding After a Facelift Procedure. *Aesthetic Plast. Surg.* 2008, 32, 807–809.

26. Remminghorst, U.; Renm, B.H.A. Bacterial alginates: From biosynthesis to applications. *Biotechnol. Lett.* 2006, 28, 1701–1712.

27. Smidsrød, O.; Haug, A.; Larsen, B. The Influence of pH on the Rate of Hydrolysis of Acidic Polysaccharides. *Acta Chem. Scand.* 1966, 20, 1026–1034.

Polysaccharides. *Acta Chem. Scand.* 1966, 20, 1026–1034.

4.2. Cellulose

28. Ojeda-Hernández, D.; D'Amico, C.; Aguirre, A.; Matias, G.; Guad Jr, G.; Gomez-Pinedo, U.; Mateos-Diaz, J. C. Potential of Chitosan and Its Derivatives for Biomedical Applications in the Central Nervous System. *Front. Bioeng. Biotechnol.* 2020, 8, 389.
29. Wang, W.; Xue, C.; Mao, X. Chitosan: Structural Modification, Biological Activity and Application. *Int. J. Biol. Macromol.* 2020, 164, 4532–4546.
30. Singh, R.S.; Kaur, N.; Rana, V.; Kennedy, J.F. Recent insights on applications of pullulan in tissue engineering. *Carbohydr. Polym.* 2016, 153, 455–462.
31. Cheng, K.-C.; Demirci, A.; Catchmark, J.M. Pullulan: Biosynthesis, production, and applications. *Appl. Microbiol. Biotechnol.* 2011, 92, 29–44.

4.3. Alginate

32. Tiwari, S.; Patil, R.; Dubey, S.K.; Bahadur, P. Derivatization approaches and applications of pullulan. *Adv. Colloid Interface Sci.* 2019, 269, 296–308.
33. Pacheco-Quito, E.-M.; Ruiz-Caro, R.; Veiga, M.-D. Carrageenan: Drug Delivery Systems and Other Biomedical Applications. *Mar. Drugs* 2020, 18, 583.
34. De Rudder, G.A.; Rudolph, B.; Carrao, G. Carrageenan biotechnology. *Trends Food Sci. Technol.* 1997, 8, 389–395.
35. Mihaila, S.M.; Gaharwar, A.K.; Reis, R.L.; Marques, A.P.; Gomes, M.E.; Khademhosseini, A. Photocrosslinkable Kappa-Carrageenan Hydrogels for Tissue Engineering Applications. *Adv. Health Mater.* 2012, 2, 895–907.
36. Mokhtari, H.; Tavakoli, S.; Safarpour, F.; Kharaziha, M.; Bakhsheshi-Rad, H.; Ramakrishna, S.;

4.4. Chitosan

37. Liu, J.; Zhan, X.; Wan, J.; Wang, Y.; Wang, C. Review for carrageenan-based pharmaceutical biomaterials: Favourable physical features versus adverse biological effects. *Carbohydr. Polym.* 2014, 121, 27–36.
38. Zanfinta, P.; Saeb, M.R.; Jafari, S.H.; Mozafari, M. Application of Compatibilized Polymer Blends in Biomedical Fields. In *Compatibilization of Polymer Blends*; Elsevier: Amsterdam, The Netherlands, 2020; pp. 511–537.
39. Hu, Q.; Lu, Y.; Luo, Y. Recent advances in dextran-based drug delivery systems: From fabrication strategies to applications. *Carbohydr. Polym.* 2021, 264, 117999.
40. Tirtaatmadja, V.; Dunstan, D.E.; Boger, D.V. Rheology of dextran solutions. *J. Non-Newtonian Fluid Mech.* 2001, 97, 295–301.
41. Zarbary, K.; Limal, M.; Ang, P.; et al. Rheology and biocompatibility of high molecular weight dextran synthesized by interfacial acid-catalyzed polymerization. *Carbohydr. Polym.* 2017, 174, 646–657.

4.5. Pullulan

42. Pullulan is a linear, unbranched, neutral exopolysaccharide obtained from the fungus *Aureobasidium pullulans*; that is composed of maltotriose units interconnected by α -D-(1,6) glycosidic bonds. The three glucose units present in each maltotriose unit are in turn connected by α -D-(1,4) glycosidic bonds [30]. The distinctive linkage pattern of pullulan confers unique physicochemical properties to the biopolymer, including oxygen impermeability, adhesiveness, water solubility, and structural flexibility. Based on the strain and fermentation parameters, the pullulan can be produced in different ways. The pullulan should be well optimized to obtain the

42. Maleki, A.; Kojima, Y.; Kawai, H.; Yoshimura, A. Effect of pH on the Behavior of Hyaluronic Acid in Dilute and Semi-dilute Aqueous Solutions. *Macromol. Symp.* 2008, 234, 131–140.

43. Necas, J.; Bartosikova, L.; Brauner, P.; Kolar, J. Hyaluronic acid (hyaluronan): A review. *Vet. Med.* 2008, 53, 397–411.

44. Pisářík, M.; Bakoš, D.; Čepčan, M. Non-Newtonian properties of hyaluronic acid aqueous solution. *Colloids Surfaces A Physicochem. Eng. Asp.* 1995, 97, 197–202.

4.6. Carrageenan

45. Fallacara, A.; Baldini, E.; Manfredini, S.; Vertuani, S. Hyaluronic Acid in the Third Millennium.

Polymers 2018, 10, 701.

46. Training Manual on Gracilaria Culture and Seaweed Processing in China. Available online: <https://agris.fao.org/agris-search/search.do?recordID=XF9214351> (accessed on 28 July 2022).

47. BeMiller, J.N. An Introduction to Pectins: Structure and Properties. In *Chemistry and Function of Pectins*; Fishman, M.L., Jen, J.J., Eds.; American Chemical Society: Washington, DC, USA, 1986; pp. 2–12.

48. Willaet, W.G.; Knox, J.P.; Mikkelson, D.B. Pectin. New insights into an old polymer and the different trends in Food Sci. Technol. 2006, 17, 97–104.

49. Zia, K.M.; Tabasum, S.; Khan, M.F.; Akram, N.; Akhter, N.; Noreen, A.; Zuber, M. Recent trends on the challenges associated with the degradation of the polysaccharide, on exposure to physiological conditions, gellan gum blends with natural and synthetic polymers: A review. *Int. J. Biol. Macromol.* 2017, 109, 1068–1087.

50. Goviello, T.; Matricardi, R.; Marianucci, G.; Alhaique, F. Polysaccharide hydrogels for modified release formulations. *J. Control. Release* 2007, 119, 5–24.

51. Carolina Ramirez Hernandez, F. Use of Hyaluronic Acid in Osteointegration of Dental Implants. *Sci. Arch. Dent. Sci.* 2019, 2, 27–28.

52. Cervino, G.; Meto, A.; Fiorillo, L.; Odorici, A.; Meto, A.; D'Amico, C.; Oteri, G.; Cicciù, M. Surface Treatment of the Dental Implant with Hyaluronic Acid: An Overview of Recent Data. *Int. J. Environ. Res. Public Health* 2021, 18, 4670.

53. Lopez-Valverde, N.; Lopez-Valverde, A.; Ramirez, J. Systematic Review of Effectiveness of Carrageenan Treatments against Viral Infections. *Antibiotics* 2021, 10, 102.

54. Kim, D.H.; Lee, H.H.; Kim, S.H.; Hwang, S.H. Effectiveness of using a bioabsorbable implant (Latera) to treat nasal valve collapse in patients with nasal obstruction: Systemic review and meta-analysis. *Int. Forum Allergy Rhinol.* 2020, 10, 719–725.

55. Romo, T.; Pearson, J.M. Nasal Implants. *Facial Plast. Surg.* 2008, 16, 123–132.

56. Sciarani, A.P.; Romo, T.; Il, M. Biology and Chemistry of Facial Implants. *Facial Plast. Surg.* 2000, 16, 3–6.

- ## 4.7. Dextran

- #### 4.8. Hyaluronic Acid (HA)

- #### 4.9. Agar

- #### 4.10. Reaction

70. Otto, D.S.; de Vrijers, M.; Maday, L.; Layer, N. Coating of Antiviral Polysaccharides on Surfaces to Prevent Coronavirus Infection. *Molecules* 2020, 25, 3415. [CrossRef]

71. Lu, W.; Yang, Z.; Chen, J.; Wang, D.; Zhang, Y. Recent advances in antiviral activities and potential mechanisms of sulfated polysaccharides. *Carbohydr. Polym.* 2021, 272, 118526. [CrossRef]

Pectin defines a family of oligosaccharides and polysaccharides that share similar properties, yet are exceedingly different in their fine structures [48].

4.11. Gellan Gum

Gellan gum (GG) is a linear, negatively charged exopolysaccharide, also called as S-60 [49]. A bacterial polysaccharide called GG was initially made commercially by Kelco (now Monsanto PLC) using the bacterium *Sphingomonas elodea*. The de-esterification produces a stiff, brittle gel, while the native polysaccharide generates a weak, elastic gel [50]. At high temperatures, gellan molecules appear as random coils, but at low temperatures, they appear as double helices. GG can withstand acid and heat stress when being manufactured. It is ductile, non-toxic, biocompatible, biodegradable, and thermoresponsive. GG possesses mucoadhesive qualities. Due to its negative charge, this polysaccharide can create polyelectrolytes with polymers that have the opposite charge, such as chitosan. GG is regarded as a pseudoplastic at high shear rates. GG is not destroyed by an acidic environment and is resistant to enzymatic activity. The GG beads expand at high pH levels and remain stable at low pH levels. Additionally, it possesses a broad range of mechanical, acceptable rheological, and high processability qualities. The finest qualities of GG are its high efficiency, malleability, and gelling ability [49].

5. Biomedical Applications of Polysaccharide-Based Implantable Devices

5.1. Implants for Oral Cavity

HA is widely studied for its osteoinductive and osseointegration properties [51]. Surface treatment of HA on titanium (Ti) dental implants enhances migration, proliferation, adhesion, and differentiation of progenitor cells by enhancing the interaction between the bone and the implant (**Figure 5a**). This facilitates fixation of dental prosthesis precisely in the early loading phase, thus improving patient compliance [52]. Similarly, chitosan has also been reported to have osseointegration capacity. The Ti implants were coated with lactose-modified-chitosan (Chitlac) and this Chitlac-Ti implant was reported to have anti-inflammatory and anti-infective activity [53] (**Figure 5b**).




Figure 5. Schematic representation of: (a) Hyaluronic acid coated titanium implant; (b) Titanium implants coated with chitilac (lactose modified chitosan).

5.2. Implants for Nasal Cavity

Nasal implants are widely used for correction of internal and external nasal valve collapse, in combination also known as lateral wall insufficiency (LWI), leading to nasal obstruction, and also for the treatment of chronic rhinosinusitis (CRS) [54]. The ideal implant for the nasal cavity should be economical, non-toxic, inert, non-carcinogenic, easily available, and should be able to provide mechanical support [55][56]. Various nasal implants have been approved by the FDA, namely, Propel™ implant, Relieva Stratus™ MicroFlow spacer, the Sinu-Foam™ spacer, and many more. “Propel” is a mometasone-releasing PLGA based biodegradable implant approved for the treatment of CRS [57].

Silicon (Si) tubes are generally used as an implant for the treatment of the obstruction of nasolacrimal duct, but these implants are found to be associated with side effects such as allergic reactions and bacterial infection, which lead to failure of surgery. In order to overcome these limitations, Park et al. performed hydrophilic polysaccharide based multilayer nanofilm coating on Si-tubes, which has the capability to load as well as release antibacterial and anti-inflammatory agents, i.e., levofloxacin and prednisolone-21-acetate, respectively. They utilized chitosan (CHI) and carboxymethylcellulose (CMC) for the preparation of multilayer films for coating. They observed that CHI/CMC coated Si-tubes exhibited significant antibacterial activity by preventing the attachment of bacteria to them [58].

5.3. Bone Implants

Osteointegration between the implanted biomaterial and the surrounding bone is critical for the acceptance of implants by the human body as it eliminates the outgrowth of fibrous tissue at the bone-implant interface [59]. Polysaccharide-based biomaterials offer good potential in the treatment of critical-sized bone defects due to their tailorable chemical and biological properties. Chitosan based scaffolds are widely researched for tissue engineering purposes. Lyophilization of chitosan acetate solution results in the formation of porous interconnected structures that are ideal for cell seeding, cell migration, and nutrient supply that facilitate bone regeneration.

Electrospinning, particle aggregation, and solvent-exchange phase separation are other methods employed in the generation of chitosan scaffolds (Figure 6) [60].




Figure 6. Diagrammatic representation of chitosan based implantable scaffold for bone regeneration.

Promotion of bone regeneration can be achieved by the delivery of therapeutic agents such as growth factors via implantable biomaterials. Lee et al. developed a chitosan–silica hybrid membrane for the delivery of bone morphogenetic protein-2 (BMP-2) and evaluated the bone healing capacity using in vivo and in vitro studies. BMP-2 exhibited excellent affinity towards the hybrid membrane due to its mesoporous structure. The efficacy of the membrane to act as a carrier was established by evaluating the induction of BMP-2 mediated cellular responses such as proliferation and differentiation in cell-culture studies. In vivo studies also indicated that a short-term implantation of the hybrid membrane for about 2 weeks accelerated the healing of bone defects [61].

Tissue engineering of non-load bearing bones, such as the trabecular, maxillofacial, or craniofacial bones, involves the use of bio-polymeric scaffolds owing to their definite microarchitecture and the ability to alter the spatio-temporal distribution of therapeutic molecules at the injury site. Agarwal et al. designed a novel alginate bead-based 3D implant using metronidazole as the model drug against bone infections caused by *E. coli*. Hexagonal close packed layers of calcium alginate beads were stacked to produce a patterned array of interconnecting octahedral and tetrahedral pores. The respective average diameter of the pores was found to be 262.9 and 142.9 μm . A 2.7-fold increase in the compressive modulus was observed on incubation of the implant in simulated body fluid. The increase in the rigidity of the implant with time could be attributed to the progressive ionotropic gelation of the alginate molecules. The osteoconductive nature of the implant was confirmed through in vitro studies, in which increased expression of differentiation markers such as runx2, alkaline phosphatase, and collagen type 1 was observed in human mesenchymal stem cells [62].

The extrusion-based 3D printing technology is widely used in the fabrication of artificial bone graft substitutes that overcome the donor site complications inherently associated with autologous grafts. Bhattacharjee et al. developed a Zn^{2+} functionalized hydroxyapatite-starch composite for orthopedic applications. The poor mechanical strength of starch was hypothesized to be overcome by the formation of a zinc–starch complex. Experimental results revealed that a four-fold increase in compressive strength was achieved upon Zn^{2+} functionalization. The functionalized grafts maintained mechanical integrity throughout the 6-week dissolution study in simulated body fluid, whereas the non-functionalized HA-starch grafts were found to degrade within a week [63].

5.4. Implant for Ocular Use

Proteins and polysaccharides appear as ideal candidates for biodegradable drug delivery due to their biocompatibility, biodegradability, low immunogenicity, and pH stability under physiological conditions. Polysaccharides such as cellulose, hyaluronic acid, gelatin, collagen, xanthan gum, alginate, and chitosan have been successfully explored in drug delivery for eye diseases. These polysaccharides are extensively used as additives for improvements in permeability, contact time, and ocular absorption. Chitosan is the most widely explored polymer for ocular drug delivery due to its mucoadhesive property and inertness [64]. Manna et al. prepared intravitreal chitosan and polylactic acid-based methotrexate micro-implants to treat primary intraocular lymphoma. The results indicate that uncoated chitosan methotrexate implants administer drug approximately for 1 day, and after coating with polylactic acid, the implants show drug release for 50 days with a release rate of 0.2–2.0 $\mu\text{g/day}$ [65]. In further continuation of their previous work, to improve the methotrexate release profile, Manna et al. utilized different combinations of PLGA-PLA coating. They observed two findings after the increase in the PLA content in PLGA: (a) the initial burst release effect gets reduced, and (b) delayed swelling and biodegradation of the micro implants. After coating with different ratios of PLA-PLGA, they observed drug release of 0.2–2.0 $\mu\text{g/day}$ of methotrexate for an extended period of ~3–5 months [66].

5.5. Implants for Antiviral Therapy

The major limitation associated with antiretroviral therapy is its longer duration of treatment, leading to nonadherence to the medication [67]. In order to overcome these limitations, long-acting antiviral drug-loaded biodegradable implants have been developed which can offer sustained release of the antiretroviral drug for a considerable period of time, ranging from several weeks to months [68]. Though, the utilization of polysaccharide based coated implants for antiretroviral therapy is not yet established in the literature, various polysaccharides including heparin, galactan, fucoidan, glucan, cellulose, dextran, or dextrin have been reported to possess antiviral properties, that can be explored in the future for prevention of viral infections [69]. The layer-by-layer coating of polysaccharides on the implant surface can be used as a potential approach to prevent viral growth on implants [70]. The ability of sulfated polysaccharides to mimic the glycosaminoglycans present in the cell membrane confers it with distinct antiviral properties. Sulfated polysaccharides are known to interfere with the steps involved in the lifecycle of a virus such as adsorption, invasion, transcription, and replication and thus lead to an enhanced host immune response by accelerating the viral clearance rate. Hence, they offer a potential for further scientific and clinical research on implantable systems [71].

6. Conclusions

The use of polysaccharide-based implantable devices in the treatment of various diseases is becoming increasingly important. Polysaccharides are used in the development of implantable devices to improve its biodegradability and biocompatibility. In addition, polysaccharides also confer certain unique properties to the composites such as mechanical strength, which favors the tissue reconstruction process. Though only a few commercial products, as discussed in the previous sections, have been successfully developed, the scope of this field is emerging vastly and holds a promising potential to create a niche market. In recent times, a considerable number of efforts have been devoted towards the development of biodegradable polysaccharide implants by various researchers and it can be expected in the near future that these innovative composites can undergo scale-up and commercialization. This would serve as a breakthrough achievement in the field of biomedical sciences, thus expanding the scope of tissue engineering applications. Polysaccharide-based implanted devices or coated implants outperform synthetic or semi-synthetic polymers. Polysaccharide-based devices are now being studied/explored for their physicochemical features, which include surface morphology, in-vitro characterization, and in-vitro evaluation. However, once implanted as a medical intervention, the implants begin to integrate the unique interaction with human body elements such as cells, tissue, organs, or the endocrine system. As a result, it is critical to comprehend such a potential interaction and research the side effects of those implantable devices. Because polysaccharides are widely used in biomedical and pharmaceutical applications, further examination is required due to safety concerns. Polysaccharide-based materials are now regarded safe in terms of biocompatibility, biodegradability, and non-toxicity, although additional research should be conducted. Once, the safety of these devices is well-established, it will in turn enhance the patient acceptability. Further, the degradation rate and the mechanism of degradation has to be well-studied for each polysaccharide. The erosion rate can significantly affect the drug release. Quick degradation in the physiological environment and result in excessive release of the drug (burst release) and may also result in premature loss of strength of the polysaccharide. Thus, the degradation mechanism of each polysaccharide needs to be validated and must be well controlled so that a better idea can be obtained regarding its in-vivo behavior.